share_log

Alnylam Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

Alnylam Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

阿里拉姆制药 | 10-Q：2024财年三季报
美股SEC公告 ·  2024/10/31 20:25

Moomoo AI 已提取核心信息

Alnylam Pharmaceuticals reported Q3 2024 total revenues of $500.9 million, down 33% year-over-year due to lower collaboration revenues, while net product revenues grew 34% to $420.1 million driven by strong AMVUTTRA sales. The company posted a net loss of $111.6 million compared to net income of $147.8 million in Q3 2023.Product revenue growth was led by AMVUTTRA at $258.6 million (+74% YoY) and GIVLAARI at $71.0 million (+31% YoY), while ONPATTRO declined 38% to $50.3 million due to patient switches to AMVUTTRA. Operating expenses increased 8% to $577.8 million reflecting continued investment in R&D and commercial infrastructure.The company maintained a strong balance sheet with $2.78 billion in cash and investments. Management highlighted positive clinical trial results for vutrisiran in ATTR amyloidosis with cardiomyopathy and regulatory submissions to FDA and EMA. The company continues to advance its RNAi therapeutic pipeline while building global commercial capabilities.
Alnylam Pharmaceuticals reported Q3 2024 total revenues of $500.9 million, down 33% year-over-year due to lower collaboration revenues, while net product revenues grew 34% to $420.1 million driven by strong AMVUTTRA sales. The company posted a net loss of $111.6 million compared to net income of $147.8 million in Q3 2023.Product revenue growth was led by AMVUTTRA at $258.6 million (+74% YoY) and GIVLAARI at $71.0 million (+31% YoY), while ONPATTRO declined 38% to $50.3 million due to patient switches to AMVUTTRA. Operating expenses increased 8% to $577.8 million reflecting continued investment in R&D and commercial infrastructure.The company maintained a strong balance sheet with $2.78 billion in cash and investments. Management highlighted positive clinical trial results for vutrisiran in ATTR amyloidosis with cardiomyopathy and regulatory submissions to FDA and EMA. The company continues to advance its RNAi therapeutic pipeline while building global commercial capabilities.
阿里拉姆制药报告2024年第三季度总营业收入为$50090万，同比下降33%，主要因合作收入减少，而产品营业收入增长34%至$42010万，得益于AMVUTTRA的强劲销售。与2023年第三季度的净利润$14780万相比，公司录得净亏损$11160万。产品收入的增长主要由AMVUTTRA推动，达到$25860万（同比增长74%）和GIVLAARI达到$7100万（同比增长31%），而由于患者更换为AMVUTTRA，ONPATTRO下降了38%，降至$5030万。营业费用增加8%，达到$57780万，反映出持续在研发和制造行业的投资。公司保持强劲的资产负债表，现金和投资总额为$27.8亿。管理层强调了vutrisiran在ATTR淀粉样变病心肌病的临床试验结果积极，以及向FDA和EMA的监管申请。公司继续推进其RNAi治疗管道，同时建立全球的商业能力。
阿里拉姆制药报告2024年第三季度总营业收入为$50090万，同比下降33%，主要因合作收入减少，而产品营业收入增长34%至$42010万，得益于AMVUTTRA的强劲销售。与2023年第三季度的净利润$14780万相比，公司录得净亏损$11160万。产品收入的增长主要由AMVUTTRA推动，达到$25860万（同比增长74%）和GIVLAARI达到$7100万（同比增长31%），而由于患者更换为AMVUTTRA，ONPATTRO下降了38%，降至$5030万。营业费用增加8%，达到$57780万，反映出持续在研发和制造行业的投资。公司保持强劲的资产负债表，现金和投资总额为$27.8亿。管理层强调了vutrisiran在ATTR淀粉样变病心肌病的临床试验结果积极，以及向FDA和EMA的监管申请。公司继续推进其RNAi治疗管道，同时建立全球的商业能力。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Portage Biotech
    PRTG
    -- 9.600
    莱斯康制药
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日